Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laekna, Inc. ( (HK:2105) ) has issued an announcement.
Laekna, Inc. announced positive preliminary results from their Phase I multiple ascending dose study of LAE102, aimed at treating obesity. The study showed promising trends in increasing lean body mass and reducing fat mass among participants, with a well-tolerated safety profile and no serious adverse events. These results support further clinical development and potential partnerships to accelerate the commercialization of LAE102, positioning it as a promising candidate for effective weight control.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.45 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biotechnology company focused on the development of innovative therapies, particularly in the field of obesity treatment. The company is engaged in the clinical development of LAE102, a monoclonal antibody targeting ActRIIA, which plays a significant role in muscle regeneration and lipid metabolism.
Average Trading Volume: 4,349,127
Technical Sentiment Signal: Buy
For an in-depth examination of 2105 stock, go to TipRanks’ Overview page.